Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Lexeo Therapeutics Inc
LXEO
Healthcare
Biotechnology
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver...
a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hype...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:LXEO)
New Post
View:
Posts & Comments
Threaded Posts
(235)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Oct 07, 2025 8:41am
Using technical analysis for this stock.
It is showing strength to the upside for shareholders today anyway,so good luck to all
(235)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Mar 24, 2025 2:44pm
Buy buddy buy.
It looks like the bottom price per share is past and the future looks good for shareholders
Scaling for long-term success: A new era in gold development
posted Dec 11, 2025 9:00am by
Vista Gold Corp.
-
|
Backed by years of technical expertise and strategic discipline, Mt Todd has emerged as one of the most compelling undeveloped gold assets globally. A recently completed feasibility study signals a pivotal shift in strategy ...read more
(235)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Jul 15, 2024 9:06pm
Geriatric medical company
Working on old folks medical problems that includes me too,since I am a baby boomer,and a lot of my friends and my relatives too are being diagnosed with these conditions.
(235)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Jul 15, 2024 8:59pm
This is a good company
for owning in the old folks medicine,so glta.
(235)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Jul 15, 2024 8:58pm
Using dollar cost averaging for this stock.
It was a buy for me today at $12.56 per share,and will be adding more tomorrow at these low prices and maybe for the rest of this week to get a total of 10000 shares,so glta.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Lode Gold Enters into Exclusive LOI with a Mining Company to Advance Fremont Gold Project
Mt Todd has emerged as one of the most compelling undeveloped gold assets globally